Abstract
BackgroundThe safety and efficacy of galcanezumab, a monoclonal antibody directed against CGRP, were assessed in a phase 2 clinical trial NCT02192190 in patients with moderate to severe osteoarthritis (OA) knee...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have